Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia.
Woo
Yin Ling
YL
West Suffolk Hospital, Bury St Edmund's, UK.
Allard
Shuba
S
Cohen
Hannah
H
Letsky
Elizabeth
E
de Swiet
Michael
M
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D000990:Antithrombin III / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000139:chemically induced / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced*; D016896:Treatment Outcome
D000925:Anticoagulants; D000990:Antithrombin III; D001241:Aspirin; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid